Recently, Antimicrobial Agents and Chemotherapy® (AAC) accepted our manuscript entitled: “Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in China: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016)”. (https://aac.asm.org/content/early/2019/01/04/AAC.02262-18.abstract?papetoc)
In this microbiology study, a total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong and Taiwan) in this study. Omadacycline showed potent in vitro activity against the organisms most frequently encountered in bacterial skin infection and community-acquired pneumonia. In addition, omadacycline showed excellent activity against problem pathogens, such as MRSA, VRE, penicillin-resistant S. pneumoniae, and ESBL-producing E. coli. The observed MIC profile in Chinese isolates was very similar to that seen in other large surveillance studies conducted in the US and Europe.
Omadacycline is a new tetracycline derivative (aminomethylcycline) available in both oral (PO) and intravenous (IV) formulations. In 2017, Zai Lab obtained an exclusive license from Paratek Pharmaceuticals.to develop, manufacture and commercialize Omadacycline in mainland China, Hong Kong, Macau and Taiwan. Omadacycline was approved by FDA in October 2018 for both skin infections (ABSSSI) and community-acquired pneumonia (CABP).
Antimicrobial Agents and Chemotherapy® (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy, and is one of the most influential magazines in the field of of microbiology and anti-infectives.